Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego

2024-04-04

临床1期AACR会议

Debiopharm announces poster presentations on data for their potentially best-in class compounds: Debio 0123, a brain-penetrant WEE1 inhibitor WEE1 inhibitor, and Debio 0432, a selective USP1 Inhibitor USP1 Inhibitor LAUSANNE, Switzerland--(BUSINESS WIRE)-- Debiopharm ( ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California. “Since 2017, Debiopharm has been growing its expertise in the DDR inhibitor field, firstly through its WEE1-inhibitor Debio 0123 and through the recently in-licensed asset, targeting USP1. These posters are proof of our commitment to stay at the forefront of DDR-inhibitor development and outsmart hard-to-treat cancers through synthetic lethality or other groundbreaking combinations.” - Angela Zubel, Chief Development Officer at Debiopharm AACR 2024 Poster Presentations Debiopharm compound Title Presenter Mon, April 8th Poster display: 9:00-12:30pm Abstract #: CT064 Poster Section: 48 Poster Board #: 14 Debio 0123 Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor WEE1 inhibitor Debio 0123 assessed in a Phase 1 dose escalation study Anne Bellon, Clinical Pharmacology Lead Mon, April 8th Poster display: 1:30-5:00pm Abstract #: 3370 Poster Section: 29 Poster Board #: 27 Debio 0123 Anti-tumor activity of Debio 0123 in combination with sacituzumab govitecan in preclinical models of breast cancer Luke Piggott, Principal Scientist Tue, April 9th Poster display: 1:30-5:00pm Abstract #: 6507 Poster Section: 46 Poster Board #: 24 Debio 0123 Simulation driven identification of combination for the WEE1 inhibitor WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated in vivo Luke Piggott, Principal Scientist & Turbine AI Wed, April 10th Poster display: 9:00-12:30pm Abstract #: 7145 Poster Section: 23 Poster Board #: 7 Debio 0432 Identification of Debio 0432 as a potent and selective USP1 inhibitor USP1 inhibitor for cancer therapy Noemie Luong, Associate Principal Scientist About DNA-Damage Repair (DDR) When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debiopharm's WEE1 and USP1 inhibitors USP1 inhibitors, are being tested in clinical and preclinical studies. Debiopharm’s commitment to cancer patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally. Visit us Follow us @DebiopharmNews

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构